Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 5, 2005, Pages 441-446

  Sparrow, M P ^a   Hande, S A ^b   Friedman, S ^b   Lim, W C ^a   Reddy, S I ^b   Cao, D ^c   Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 TIOGUANINE; ALLOPURINOL; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; COLITIS; COLON CROHN DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE COUNT; HUMAN; LEUKOCYTE COUNT; PRIORITY JOURNAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ALLOPURINOL; ANTIMETABOLITES; AZATHIOPRINE; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; THIOGUANINE;

EID: 24344480999     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02583.x     Document Type: Article

References (15)

1. Pearson DC, May GR, Fick GH, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000(2): CD000067.
2. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2.
3. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
4. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-9.
5. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
6. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
7. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
8. Dubinsky MC, Yang HY, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
9. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
10. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
11. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342: 83-4.
12. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
13. Weyer N, Kroplin T, Fricke L, et al. Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol 2001; 57: 129-36.
14. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002; 9: 195-217.
15. Olah T, Regely K, Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 96-9.